Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

Official Title

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Keywords

Cardiomyopathy, Hypertrophic, Mavacamten, non-obstructive HCM, non-obstructive hypertrophic cardiomyopathy (nHCM), Cardiomyopathies, Hypertrophic Cardiomyopathy, Hypertrophy

Eligibility

Locations

  • Local Institution - 0406
    San Francisco California 94143-2204 United States
  • Local Institution - 0079
    Stanford California 94305-2200 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
ID
NCT05582395
Phase
Phase 3 Cardiomyopathy Research Study
Study Type
Interventional
Participants
About 580 people participating
Last Updated